The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) recommended the following changes for use of tetanus toxoid, reduced content diphtheria toxoid and pertussis antigen (Tdap) vaccine in children and adults:

The Vaccines for Children Program will cover relevant indications.

The recommendations are the conclusions of the CDC Workgroup on Pertussis, which was charged with reviewing evidence and advising the ACIP on Tdap issues. Chaired by Mark Sawyer, M.D., FAAP, the workgroup included liaison members from multiple organizations, including the AAP Committee on Infectious Diseases (COID). The COID has approved the changes, and the recommendations will be incorporated into the 2012 Red Book.

When Tdap was licensed in 2006 and universal adolescent immunization was recommended, there were few data on reactogenicity of Tdap given within a short interval of another tetanus- or diphtheria-toxoid-containing vaccine. Thus, it was recommended that the minimum interval...

You do not currently have access to this content.